{
  "id": "breast-cancer-cdk46-main",
  "display_name": "ER+/HER2- MBC (Main)",
  "cohort": "ER+/HER2- Metastatic Breast Cancer, All Patients, Q1 2023",
  "insight_type": "Treatment Patterns by Regimen",
  "summary": "Standard of care abemaciclib CDK4/6 utilization is at 80% for eligible patients, aligning with NCCN guidelines.",
  "recommendation": "Continue to maintain high standard of care utilization, particularly focusing on maintaining guideline adherence.",
  "financial_impact": {
    "annual_opportunity": "$0/year",
    "math": "Current practice is aligned with best practices."
  },
  "financial_impact_description": "Current practice is aligned with best practices.",
  "peer_financial_impact": 0,
  "peer_financial_impact_description": "Your organization is performing well compared to peers.",
  "action_steps": [
    {
      "text": "Continue to monitor CDK4/6 inhibitor utilization",
      "icon": "chart-bar"
    },
    {
      "text": "No immediate action required",
      "icon": "user-group"
    }
  ],
  "peer_action_steps": [
    "Continue current practices",
    "Consider sharing best practices with underperforming organizations"
  ],
  "chart_data": {
    "categories": [
      "Abemaciclib",
      "Palbociclib",
      "Ribociclib",
      "Everolimus",
      "Other"
    ],
    "values": [
      80,
      10,
      5,
      3,
      2
    ],
    "peer_values": [
      65,
      20,
      8,
      5,
      2
    ],
    "target_values": [
      85,
      10,
      5,
      0,
      0
    ]
  },
  "drilldowns": [
    {
      "label": "View by Site",
      "description": "Compare regimen utilization by site",
      "jsonFile": "breast-cancer-cdk46-by-site.json"
    },
    {
      "label": "View by Payer",
      "description": "Compare regimen utilization by payer type",
      "jsonFile": "breast-cancer-cdk46-by-payer.json"
    },
    {
      "label": "View by Regimen",
      "description": "Compare regimen utilization in detail",
      "jsonFile": "breast-cancer-cdk46-by-regimen.json"
    }
  ],
  "chart": {
    "type": "bar",
    "unit": "provider",
    "data": [
      {
        "name": "Abemaciclib",
        "value": 80,
        "gap": 0,
        "highlight": true
      },
      {
        "name": "Palbociclib",
        "value": 10,
        "gap": 0,
        "highlight": false
      },
      {
        "name": "Ribociclib",
        "value": 5,
        "gap": 0,
        "highlight": false
      },
      {
        "name": "Everolimus",
        "value": 3,
        "gap": 0,
        "highlight": false
      },
      {
        "name": "Other",
        "value": 2,
        "gap": 0,
        "highlight": false
      }
    ],
    "benchmark": 65,
    "nccn_target": 65
  },
  "clinical_impact": {
    "description": "Clinical impact analysis based on outcomes data and peer-reviewed literature.",
    "metrics": [
      {
        "type": "PFS",
        "value": "+3.2 months",
        "description": "Potential median progression-free survival improvement"
      },
      {
        "type": "OS",
        "value": "+5.1 months",
        "description": "Potential median overall survival improvement"
      },
      {
        "type": "QoL",
        "value": "+15%",
        "description": "Enhanced quality of life measures"
      }
    ],
    "quantitative": "+5.1 months OS"
  },
  "weighted_score": 70
}